Global Biosimilar and Biologics Market Growth 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
The global Biosimilar and Biologics market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Biosimilar and Biologics Industry Forecast” looks at past sales and reviews total world Biosimilar and Biologics sales in 2023, providing a comprehensive analysis by region and market sector of projected Biosimilar and Biologics sales for 2024 through 2030. With Biosimilar and Biologics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biosimilar and Biologics industry.
This Insight Report provides a comprehensive analysis of the global Biosimilar and Biologics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Biosimilar and Biologics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Biosimilar and Biologics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biosimilar and Biologics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biosimilar and Biologics.
United States market for Biosimilar and Biologics is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Biosimilar and Biologics is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Biosimilar and Biologics is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Biosimilar and Biologics players cover Pfizer, Roche AG, AbbVie, Novartis AG and Merck, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Biosimilar and Biologics market by product type, application, key manufacturers and key regions and countries.
Segmentation by type
What is the 10-year outlook for the global Biosimilar and Biologics market?
What factors are driving Biosimilar and Biologics market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Biosimilar and Biologics market opportunities vary by end market size?
How does Biosimilar and Biologics break out type, application?
The global Biosimilar and Biologics market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Biosimilar and Biologics Industry Forecast” looks at past sales and reviews total world Biosimilar and Biologics sales in 2023, providing a comprehensive analysis by region and market sector of projected Biosimilar and Biologics sales for 2024 through 2030. With Biosimilar and Biologics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biosimilar and Biologics industry.
This Insight Report provides a comprehensive analysis of the global Biosimilar and Biologics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Biosimilar and Biologics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Biosimilar and Biologics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biosimilar and Biologics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biosimilar and Biologics.
United States market for Biosimilar and Biologics is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Biosimilar and Biologics is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Biosimilar and Biologics is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Biosimilar and Biologics players cover Pfizer, Roche AG, AbbVie, Novartis AG and Merck, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Biosimilar and Biologics market by product type, application, key manufacturers and key regions and countries.
Segmentation by type
- Monoclonal Antibody
- Vaccines
- Recombinant Insulin
- Growth Factors
- Immune Modulators
- Fusion Protein
- Erythoprotein
- Other
- Autoimmune Diseases
- Infectious Diseases
- Cardiovascular Disorders
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Pfizer
- Roche AG
- AbbVie
- Novartis AG
- Merck
- Bristol Myers Squibb
- GSK
- AstraZeneca
- Eli Lilly
- Bayer
- Gilead Sciences
- Amgen
- Boehringer Ingelheim
- Novo Nordisk
- Viatris
- Johnson
- Sanofi Winthrop Industries
- Serum Institute of India
- Biocon
- Intas Pharmaceuticals
What is the 10-year outlook for the global Biosimilar and Biologics market?
What factors are driving Biosimilar and Biologics market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Biosimilar and Biologics market opportunities vary by end market size?
How does Biosimilar and Biologics break out type, application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Biosimilar and Biologics Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Biosimilar and Biologics by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Biosimilar and Biologics by Country/Region, 2019, 2023 & 2030
2.2 Biosimilar and Biologics Segment by Type
2.2.1 Monoclonal Antibody
2.2.2 Vaccines
2.2.3 Recombinant Insulin
2.2.4 Growth Factors
2.2.5 Immune Modulators
2.2.6 Fusion Protein
2.2.7 Erythoprotein
2.2.8 Other
2.3 Biosimilar and Biologics Sales by Type
2.3.1 Global Biosimilar and Biologics Sales Market Share by Type (2019-2024)
2.3.2 Global Biosimilar and Biologics Revenue and Market Share by Type (2019-2024)
2.3.3 Global Biosimilar and Biologics Sale Price by Type (2019-2024)
2.4 Biosimilar and Biologics Segment by Application
2.4.1 Autoimmune Diseases
2.4.2 Infectious Diseases
2.4.3 Cardiovascular Disorders
2.4.4 Other
2.5 Biosimilar and Biologics Sales by Application
2.5.1 Global Biosimilar and Biologics Sale Market Share by Application (2019-2024)
2.5.2 Global Biosimilar and Biologics Revenue and Market Share by Application (2019-2024)
2.5.3 Global Biosimilar and Biologics Sale Price by Application (2019-2024)
3 GLOBAL BIOSIMILAR AND BIOLOGICS BY COMPANY
3.1 Global Biosimilar and Biologics Breakdown Data by Company
3.1.1 Global Biosimilar and Biologics Annual Sales by Company (2019-2024)
3.1.2 Global Biosimilar and Biologics Sales Market Share by Company (2019-2024)
3.2 Global Biosimilar and Biologics Annual Revenue by Company (2019-2024)
3.2.1 Global Biosimilar and Biologics Revenue by Company (2019-2024)
3.2.2 Global Biosimilar and Biologics Revenue Market Share by Company (2019-2024)
3.3 Global Biosimilar and Biologics Sale Price by Company
3.4 Key Manufacturers Biosimilar and Biologics Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Biosimilar and Biologics Product Location Distribution
3.4.2 Players Biosimilar and Biologics Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR BIOSIMILAR AND BIOLOGICS BY GEOGRAPHIC REGION
4.1 World Historic Biosimilar and Biologics Market Size by Geographic Region (2019-2024)
4.1.1 Global Biosimilar and Biologics Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Biosimilar and Biologics Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Biosimilar and Biologics Market Size by Country/Region (2019-2024)
4.2.1 Global Biosimilar and Biologics Annual Sales by Country/Region (2019-2024)
4.2.2 Global Biosimilar and Biologics Annual Revenue by Country/Region (2019-2024)
4.3 Americas Biosimilar and Biologics Sales Growth
4.4 APAC Biosimilar and Biologics Sales Growth
4.5 Europe Biosimilar and Biologics Sales Growth
4.6 Middle East & Africa Biosimilar and Biologics Sales Growth
5 AMERICAS
5.1 Americas Biosimilar and Biologics Sales by Country
5.1.1 Americas Biosimilar and Biologics Sales by Country (2019-2024)
5.1.2 Americas Biosimilar and Biologics Revenue by Country (2019-2024)
5.2 Americas Biosimilar and Biologics Sales by Type
5.3 Americas Biosimilar and Biologics Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Biosimilar and Biologics Sales by Region
6.1.1 APAC Biosimilar and Biologics Sales by Region (2019-2024)
6.1.2 APAC Biosimilar and Biologics Revenue by Region (2019-2024)
6.2 APAC Biosimilar and Biologics Sales by Type
6.3 APAC Biosimilar and Biologics Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Biosimilar and Biologics by Country
7.1.1 Europe Biosimilar and Biologics Sales by Country (2019-2024)
7.1.2 Europe Biosimilar and Biologics Revenue by Country (2019-2024)
7.2 Europe Biosimilar and Biologics Sales by Type
7.3 Europe Biosimilar and Biologics Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Biosimilar and Biologics by Country
8.1.1 Middle East & Africa Biosimilar and Biologics Sales by Country (2019-2024)
8.1.2 Middle East & Africa Biosimilar and Biologics Revenue by Country (2019-2024)
8.2 Middle East & Africa Biosimilar and Biologics Sales by Type
8.3 Middle East & Africa Biosimilar and Biologics Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Biosimilar and Biologics
10.3 Manufacturing Process Analysis of Biosimilar and Biologics
10.4 Industry Chain Structure of Biosimilar and Biologics
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Biosimilar and Biologics Distributors
11.3 Biosimilar and Biologics Customer
12 WORLD FORECAST REVIEW FOR BIOSIMILAR AND BIOLOGICS BY GEOGRAPHIC REGION
12.1 Global Biosimilar and Biologics Market Size Forecast by Region
12.1.1 Global Biosimilar and Biologics Forecast by Region (2025-2030)
12.1.2 Global Biosimilar and Biologics Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Biosimilar and Biologics Forecast by Type
12.7 Global Biosimilar and Biologics Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Biosimilar and Biologics Product Portfolios and Specifications
13.1.3 Pfizer Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Roche AG
13.2.1 Roche AG Company Information
13.2.2 Roche AG Biosimilar and Biologics Product Portfolios and Specifications
13.2.3 Roche AG Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Roche AG Main Business Overview
13.2.5 Roche AG Latest Developments
13.3 AbbVie
13.3.1 AbbVie Company Information
13.3.2 AbbVie Biosimilar and Biologics Product Portfolios and Specifications
13.3.3 AbbVie Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 AbbVie Main Business Overview
13.3.5 AbbVie Latest Developments
13.4 Novartis AG
13.4.1 Novartis AG Company Information
13.4.2 Novartis AG Biosimilar and Biologics Product Portfolios and Specifications
13.4.3 Novartis AG Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Novartis AG Main Business Overview
13.4.5 Novartis AG Latest Developments
13.5 Merck
13.5.1 Merck Company Information
13.5.2 Merck Biosimilar and Biologics Product Portfolios and Specifications
13.5.3 Merck Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Merck Main Business Overview
13.5.5 Merck Latest Developments
13.6 Bristol Myers Squibb
13.6.1 Bristol Myers Squibb Company Information
13.6.2 Bristol Myers Squibb Biosimilar and Biologics Product Portfolios and Specifications
13.6.3 Bristol Myers Squibb Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Bristol Myers Squibb Main Business Overview
13.6.5 Bristol Myers Squibb Latest Developments
13.7 GSK
13.7.1 GSK Company Information
13.7.2 GSK Biosimilar and Biologics Product Portfolios and Specifications
13.7.3 GSK Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 GSK Main Business Overview
13.7.5 GSK Latest Developments
13.8 AstraZeneca
13.8.1 AstraZeneca Company Information
13.8.2 AstraZeneca Biosimilar and Biologics Product Portfolios and Specifications
13.8.3 AstraZeneca Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 AstraZeneca Main Business Overview
13.8.5 AstraZeneca Latest Developments
13.9 Eli Lilly
13.9.1 Eli Lilly Company Information
13.9.2 Eli Lilly Biosimilar and Biologics Product Portfolios and Specifications
13.9.3 Eli Lilly Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Eli Lilly Main Business Overview
13.9.5 Eli Lilly Latest Developments
13.10 Bayer
13.10.1 Bayer Company Information
13.10.2 Bayer Biosimilar and Biologics Product Portfolios and Specifications
13.10.3 Bayer Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Bayer Main Business Overview
13.10.5 Bayer Latest Developments
13.11 Gilead Sciences
13.11.1 Gilead Sciences Company Information
13.11.2 Gilead Sciences Biosimilar and Biologics Product Portfolios and Specifications
13.11.3 Gilead Sciences Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Gilead Sciences Main Business Overview
13.11.5 Gilead Sciences Latest Developments
13.12 Amgen
13.12.1 Amgen Company Information
13.12.2 Amgen Biosimilar and Biologics Product Portfolios and Specifications
13.12.3 Amgen Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Amgen Main Business Overview
13.12.5 Amgen Latest Developments
13.13 Boehringer Ingelheim
13.13.1 Boehringer Ingelheim Company Information
13.13.2 Boehringer Ingelheim Biosimilar and Biologics Product Portfolios and Specifications
13.13.3 Boehringer Ingelheim Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Boehringer Ingelheim Main Business Overview
13.13.5 Boehringer Ingelheim Latest Developments
13.14 Novo Nordisk
13.14.1 Novo Nordisk Company Information
13.14.2 Novo Nordisk Biosimilar and Biologics Product Portfolios and Specifications
13.14.3 Novo Nordisk Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Novo Nordisk Main Business Overview
13.14.5 Novo Nordisk Latest Developments
13.15 Viatris
13.15.1 Viatris Company Information
13.15.2 Viatris Biosimilar and Biologics Product Portfolios and Specifications
13.15.3 Viatris Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 Viatris Main Business Overview
13.15.5 Viatris Latest Developments
13.16 Johnson
13.16.1 Johnson Company Information
13.16.2 Johnson Biosimilar and Biologics Product Portfolios and Specifications
13.16.3 Johnson Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.16.4 Johnson Main Business Overview
13.16.5 Johnson Latest Developments
13.17 Sanofi Winthrop Industries
13.17.1 Sanofi Winthrop Industries Company Information
13.17.2 Sanofi Winthrop Industries Biosimilar and Biologics Product Portfolios and Specifications
13.17.3 Sanofi Winthrop Industries Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.17.4 Sanofi Winthrop Industries Main Business Overview
13.17.5 Sanofi Winthrop Industries Latest Developments
13.18 Serum Institute of India
13.18.1 Serum Institute of India Company Information
13.18.2 Serum Institute of India Biosimilar and Biologics Product Portfolios and Specifications
13.18.3 Serum Institute of India Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.18.4 Serum Institute of India Main Business Overview
13.18.5 Serum Institute of India Latest Developments
13.19 Biocon
13.19.1 Biocon Company Information
13.19.2 Biocon Biosimilar and Biologics Product Portfolios and Specifications
13.19.3 Biocon Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.19.4 Biocon Main Business Overview
13.19.5 Biocon Latest Developments
13.20 Intas Pharmaceuticals
13.20.1 Intas Pharmaceuticals Company Information
13.20.2 Intas Pharmaceuticals Biosimilar and Biologics Product Portfolios and Specifications
13.20.3 Intas Pharmaceuticals Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.20.4 Intas Pharmaceuticals Main Business Overview
13.20.5 Intas Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Biosimilar and Biologics Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Biosimilar and Biologics by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Biosimilar and Biologics by Country/Region, 2019, 2023 & 2030
2.2 Biosimilar and Biologics Segment by Type
2.2.1 Monoclonal Antibody
2.2.2 Vaccines
2.2.3 Recombinant Insulin
2.2.4 Growth Factors
2.2.5 Immune Modulators
2.2.6 Fusion Protein
2.2.7 Erythoprotein
2.2.8 Other
2.3 Biosimilar and Biologics Sales by Type
2.3.1 Global Biosimilar and Biologics Sales Market Share by Type (2019-2024)
2.3.2 Global Biosimilar and Biologics Revenue and Market Share by Type (2019-2024)
2.3.3 Global Biosimilar and Biologics Sale Price by Type (2019-2024)
2.4 Biosimilar and Biologics Segment by Application
2.4.1 Autoimmune Diseases
2.4.2 Infectious Diseases
2.4.3 Cardiovascular Disorders
2.4.4 Other
2.5 Biosimilar and Biologics Sales by Application
2.5.1 Global Biosimilar and Biologics Sale Market Share by Application (2019-2024)
2.5.2 Global Biosimilar and Biologics Revenue and Market Share by Application (2019-2024)
2.5.3 Global Biosimilar and Biologics Sale Price by Application (2019-2024)
3 GLOBAL BIOSIMILAR AND BIOLOGICS BY COMPANY
3.1 Global Biosimilar and Biologics Breakdown Data by Company
3.1.1 Global Biosimilar and Biologics Annual Sales by Company (2019-2024)
3.1.2 Global Biosimilar and Biologics Sales Market Share by Company (2019-2024)
3.2 Global Biosimilar and Biologics Annual Revenue by Company (2019-2024)
3.2.1 Global Biosimilar and Biologics Revenue by Company (2019-2024)
3.2.2 Global Biosimilar and Biologics Revenue Market Share by Company (2019-2024)
3.3 Global Biosimilar and Biologics Sale Price by Company
3.4 Key Manufacturers Biosimilar and Biologics Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Biosimilar and Biologics Product Location Distribution
3.4.2 Players Biosimilar and Biologics Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR BIOSIMILAR AND BIOLOGICS BY GEOGRAPHIC REGION
4.1 World Historic Biosimilar and Biologics Market Size by Geographic Region (2019-2024)
4.1.1 Global Biosimilar and Biologics Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Biosimilar and Biologics Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Biosimilar and Biologics Market Size by Country/Region (2019-2024)
4.2.1 Global Biosimilar and Biologics Annual Sales by Country/Region (2019-2024)
4.2.2 Global Biosimilar and Biologics Annual Revenue by Country/Region (2019-2024)
4.3 Americas Biosimilar and Biologics Sales Growth
4.4 APAC Biosimilar and Biologics Sales Growth
4.5 Europe Biosimilar and Biologics Sales Growth
4.6 Middle East & Africa Biosimilar and Biologics Sales Growth
5 AMERICAS
5.1 Americas Biosimilar and Biologics Sales by Country
5.1.1 Americas Biosimilar and Biologics Sales by Country (2019-2024)
5.1.2 Americas Biosimilar and Biologics Revenue by Country (2019-2024)
5.2 Americas Biosimilar and Biologics Sales by Type
5.3 Americas Biosimilar and Biologics Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Biosimilar and Biologics Sales by Region
6.1.1 APAC Biosimilar and Biologics Sales by Region (2019-2024)
6.1.2 APAC Biosimilar and Biologics Revenue by Region (2019-2024)
6.2 APAC Biosimilar and Biologics Sales by Type
6.3 APAC Biosimilar and Biologics Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Biosimilar and Biologics by Country
7.1.1 Europe Biosimilar and Biologics Sales by Country (2019-2024)
7.1.2 Europe Biosimilar and Biologics Revenue by Country (2019-2024)
7.2 Europe Biosimilar and Biologics Sales by Type
7.3 Europe Biosimilar and Biologics Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Biosimilar and Biologics by Country
8.1.1 Middle East & Africa Biosimilar and Biologics Sales by Country (2019-2024)
8.1.2 Middle East & Africa Biosimilar and Biologics Revenue by Country (2019-2024)
8.2 Middle East & Africa Biosimilar and Biologics Sales by Type
8.3 Middle East & Africa Biosimilar and Biologics Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Biosimilar and Biologics
10.3 Manufacturing Process Analysis of Biosimilar and Biologics
10.4 Industry Chain Structure of Biosimilar and Biologics
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Biosimilar and Biologics Distributors
11.3 Biosimilar and Biologics Customer
12 WORLD FORECAST REVIEW FOR BIOSIMILAR AND BIOLOGICS BY GEOGRAPHIC REGION
12.1 Global Biosimilar and Biologics Market Size Forecast by Region
12.1.1 Global Biosimilar and Biologics Forecast by Region (2025-2030)
12.1.2 Global Biosimilar and Biologics Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Biosimilar and Biologics Forecast by Type
12.7 Global Biosimilar and Biologics Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Biosimilar and Biologics Product Portfolios and Specifications
13.1.3 Pfizer Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Roche AG
13.2.1 Roche AG Company Information
13.2.2 Roche AG Biosimilar and Biologics Product Portfolios and Specifications
13.2.3 Roche AG Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Roche AG Main Business Overview
13.2.5 Roche AG Latest Developments
13.3 AbbVie
13.3.1 AbbVie Company Information
13.3.2 AbbVie Biosimilar and Biologics Product Portfolios and Specifications
13.3.3 AbbVie Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 AbbVie Main Business Overview
13.3.5 AbbVie Latest Developments
13.4 Novartis AG
13.4.1 Novartis AG Company Information
13.4.2 Novartis AG Biosimilar and Biologics Product Portfolios and Specifications
13.4.3 Novartis AG Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Novartis AG Main Business Overview
13.4.5 Novartis AG Latest Developments
13.5 Merck
13.5.1 Merck Company Information
13.5.2 Merck Biosimilar and Biologics Product Portfolios and Specifications
13.5.3 Merck Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Merck Main Business Overview
13.5.5 Merck Latest Developments
13.6 Bristol Myers Squibb
13.6.1 Bristol Myers Squibb Company Information
13.6.2 Bristol Myers Squibb Biosimilar and Biologics Product Portfolios and Specifications
13.6.3 Bristol Myers Squibb Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Bristol Myers Squibb Main Business Overview
13.6.5 Bristol Myers Squibb Latest Developments
13.7 GSK
13.7.1 GSK Company Information
13.7.2 GSK Biosimilar and Biologics Product Portfolios and Specifications
13.7.3 GSK Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 GSK Main Business Overview
13.7.5 GSK Latest Developments
13.8 AstraZeneca
13.8.1 AstraZeneca Company Information
13.8.2 AstraZeneca Biosimilar and Biologics Product Portfolios and Specifications
13.8.3 AstraZeneca Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 AstraZeneca Main Business Overview
13.8.5 AstraZeneca Latest Developments
13.9 Eli Lilly
13.9.1 Eli Lilly Company Information
13.9.2 Eli Lilly Biosimilar and Biologics Product Portfolios and Specifications
13.9.3 Eli Lilly Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Eli Lilly Main Business Overview
13.9.5 Eli Lilly Latest Developments
13.10 Bayer
13.10.1 Bayer Company Information
13.10.2 Bayer Biosimilar and Biologics Product Portfolios and Specifications
13.10.3 Bayer Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Bayer Main Business Overview
13.10.5 Bayer Latest Developments
13.11 Gilead Sciences
13.11.1 Gilead Sciences Company Information
13.11.2 Gilead Sciences Biosimilar and Biologics Product Portfolios and Specifications
13.11.3 Gilead Sciences Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Gilead Sciences Main Business Overview
13.11.5 Gilead Sciences Latest Developments
13.12 Amgen
13.12.1 Amgen Company Information
13.12.2 Amgen Biosimilar and Biologics Product Portfolios and Specifications
13.12.3 Amgen Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Amgen Main Business Overview
13.12.5 Amgen Latest Developments
13.13 Boehringer Ingelheim
13.13.1 Boehringer Ingelheim Company Information
13.13.2 Boehringer Ingelheim Biosimilar and Biologics Product Portfolios and Specifications
13.13.3 Boehringer Ingelheim Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Boehringer Ingelheim Main Business Overview
13.13.5 Boehringer Ingelheim Latest Developments
13.14 Novo Nordisk
13.14.1 Novo Nordisk Company Information
13.14.2 Novo Nordisk Biosimilar and Biologics Product Portfolios and Specifications
13.14.3 Novo Nordisk Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Novo Nordisk Main Business Overview
13.14.5 Novo Nordisk Latest Developments
13.15 Viatris
13.15.1 Viatris Company Information
13.15.2 Viatris Biosimilar and Biologics Product Portfolios and Specifications
13.15.3 Viatris Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 Viatris Main Business Overview
13.15.5 Viatris Latest Developments
13.16 Johnson
13.16.1 Johnson Company Information
13.16.2 Johnson Biosimilar and Biologics Product Portfolios and Specifications
13.16.3 Johnson Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.16.4 Johnson Main Business Overview
13.16.5 Johnson Latest Developments
13.17 Sanofi Winthrop Industries
13.17.1 Sanofi Winthrop Industries Company Information
13.17.2 Sanofi Winthrop Industries Biosimilar and Biologics Product Portfolios and Specifications
13.17.3 Sanofi Winthrop Industries Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.17.4 Sanofi Winthrop Industries Main Business Overview
13.17.5 Sanofi Winthrop Industries Latest Developments
13.18 Serum Institute of India
13.18.1 Serum Institute of India Company Information
13.18.2 Serum Institute of India Biosimilar and Biologics Product Portfolios and Specifications
13.18.3 Serum Institute of India Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.18.4 Serum Institute of India Main Business Overview
13.18.5 Serum Institute of India Latest Developments
13.19 Biocon
13.19.1 Biocon Company Information
13.19.2 Biocon Biosimilar and Biologics Product Portfolios and Specifications
13.19.3 Biocon Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.19.4 Biocon Main Business Overview
13.19.5 Biocon Latest Developments
13.20 Intas Pharmaceuticals
13.20.1 Intas Pharmaceuticals Company Information
13.20.2 Intas Pharmaceuticals Biosimilar and Biologics Product Portfolios and Specifications
13.20.3 Intas Pharmaceuticals Biosimilar and Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
13.20.4 Intas Pharmaceuticals Main Business Overview
13.20.5 Intas Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Biosimilar and Biologics Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Biosimilar and Biologics Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Monoclonal Antibody
Table 4. Major Players of Vaccines
Table 5. Major Players of Recombinant Insulin
Table 6. Major Players of Growth Factors
Table 7. Major Players of Immune Modulators
Table 8. Major Players of Fusion Protein
Table 9. Major Players of Erythoprotein
Table 10. Major Players of Other
Table 11. Global Biosimilar and Biologics Sales by Type (2019-2024) & (K Units)
Table 12. Global Biosimilar and Biologics Sales Market Share by Type (2019-2024)
Table 13. Global Biosimilar and Biologics Revenue by Type (2019-2024) & ($ million)
Table 14. Global Biosimilar and Biologics Revenue Market Share by Type (2019-2024)
Table 15. Global Biosimilar and Biologics Sale Price by Type (2019-2024) & (US$/Unit)
Table 16. Global Biosimilar and Biologics Sales by Application (2019-2024) & (K Units)
Table 17. Global Biosimilar and Biologics Sales Market Share by Application (2019-2024)
Table 18. Global Biosimilar and Biologics Revenue by Application (2019-2024)
Table 19. Global Biosimilar and Biologics Revenue Market Share by Application (2019-2024)
Table 20. Global Biosimilar and Biologics Sale Price by Application (2019-2024) & (US$/Unit)
Table 21. Global Biosimilar and Biologics Sales by Company (2019-2024) & (K Units)
Table 22. Global Biosimilar and Biologics Sales Market Share by Company (2019-2024)
Table 23. Global Biosimilar and Biologics Revenue by Company (2019-2024) ($ Millions)
Table 24. Global Biosimilar and Biologics Revenue Market Share by Company (2019-2024)
Table 25. Global Biosimilar and Biologics Sale Price by Company (2019-2024) & (US$/Unit)
Table 26. Key Manufacturers Biosimilar and Biologics Producing Area Distribution and Sales Area
Table 27. Players Biosimilar and Biologics Products Offered
Table 28. Biosimilar and Biologics Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 29. New Products and Potential Entrants
Table 30. Mergers & Acquisitions, Expansion
Table 31. Global Biosimilar and Biologics Sales by Geographic Region (2019-2024) & (K Units)
Table 32. Global Biosimilar and Biologics Sales Market Share Geographic Region (2019-2024)
Table 33. Global Biosimilar and Biologics Revenue by Geographic Region (2019-2024) & ($ millions)
Table 34. Global Biosimilar and Biologics Revenue Market Share by Geographic Region (2019-2024)
Table 35. Global Biosimilar and Biologics Sales by Country/Region (2019-2024) & (K Units)
Table 36. Global Biosimilar and Biologics Sales Market Share by Country/Region (2019-2024)
Table 37. Global Biosimilar and Biologics Revenue by Country/Region (2019-2024) & ($ millions)
Table 38. Global Biosimilar and Biologics Revenue Market Share by Country/Region (2019-2024)
Table 39. Americas Biosimilar and Biologics Sales by Country (2019-2024) & (K Units)
Table 40. Americas Biosimilar and Biologics Sales Market Share by Country (2019-2024)
Table 41. Americas Biosimilar and Biologics Revenue by Country (2019-2024) & ($ Millions)
Table 42. Americas Biosimilar and Biologics Revenue Market Share by Country (2019-2024)
Table 43. Americas Biosimilar and Biologics Sales by Type (2019-2024) & (K Units)
Table 44. Americas Biosimilar and Biologics Sales by Application (2019-2024) & (K Units)
Table 45. APAC Biosimilar and Biologics Sales by Region (2019-2024) & (K Units)
Table 46. APAC Biosimilar and Biologics Sales Market Share by Region (2019-2024)
Table 47. APAC Biosimilar and Biologics Revenue by Region (2019-2024) & ($ Millions)
Table 48. APAC Biosimilar and Biologics Revenue Market Share by Region (2019-2024)
Table 49. APAC Biosimilar and Biologics Sales by Type (2019-2024) & (K Units)
Table 50. APAC Biosimilar and Biologics Sales by Application (2019-2024) & (K Units)
Table 51. Europe Biosimilar and Biologics Sales by Country (2019-2024) & (K Units)
Table 52. Europe Biosimilar and Biologics Sales Market Share by Country (2019-2024)
Table 53. Europe Biosimilar and Biologics Revenue by Country (2019-2024) & ($ Millions)
Table 54. Europe Biosimilar and Biologics Revenue Market Share by Country (2019-2024)
Table 55. Europe Biosimilar and Biologics Sales by Type (2019-2024) & (K Units)
Table 56. Europe Biosimilar and Biologics Sales by Application (2019-2024) & (K Units)
Table 57. Middle East & Africa Biosimilar and Biologics Sales by Country (2019-2024) & (K Units)
Table 58. Middle East & Africa Biosimilar and Biologics Sales Market Share by Country (2019-2024)
Table 59. Middle East & Africa Biosimilar and Biologics Revenue by Country (2019-2024) & ($ Millions)
Table 60. Middle East & Africa Biosimilar and Biologics Revenue Market Share by Country (2019-2024)
Table 61. Middle East & Africa Biosimilar and Biologics Sales by Type (2019-2024) & (K Units)
Table 62. Middle East & Africa Biosimilar and Biologics Sales by Application (2019-2024) & (K Units)
Table 63. Key Market Drivers & Growth Opportunities of Biosimilar and Biologics
Table 64. Key Market Challenges & Risks of Biosimilar and Biologics
Table 65. Key Industry Trends of Biosimilar and Biologics
Table 66. Biosimilar and Biologics Raw Material
Table 67. Key Suppliers of Raw Materials
Table 68. Biosimilar and Biologics Distributors List
Table 69. Biosimilar and Biologics Customer List
Table 70. Global Biosimilar and Biologics Sales Forecast by Region (2025-2030) & (K Units)
Table 71. Global Biosimilar and Biologics Revenue Forecast by Region (2025-2030) & ($ millions)
Table 72. Americas Biosimilar and Biologics Sales Forecast by Country (2025-2030) & (K Units)
Table 73. Americas Biosimilar and Biologics Revenue Forecast by Country (2025-2030) & ($ millions)
Table 74. APAC Biosimilar and Biologics Sales Forecast by Region (2025-2030) & (K Units)
Table 75. APAC Biosimilar and Biologics Revenue Forecast by Region (2025-2030) & ($ millions)
Table 76. Europe Biosimilar and Biologics Sales Forecast by Country (2025-2030) & (K Units)
Table 77. Europe Biosimilar and Biologics Revenue Forecast by Country (2025-2030) & ($ millions)
Table 78. Middle East & Africa Biosimilar and Biologics Sales Forecast by Country (2025-2030) & (K Units)
Table 79. Middle East & Africa Biosimilar and Biologics Revenue Forecast by Country (2025-2030) & ($ millions)
Table 80. Global Biosimilar and Biologics Sales Forecast by Type (2025-2030) & (K Units)
Table 81. Global Biosimilar and Biologics Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 82. Global Biosimilar and Biologics Sales Forecast by Application (2025-2030) & (K Units)
Table 83. Global Biosimilar and Biologics Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 84. Pfizer Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 85. Pfizer Biosimilar and Biologics Product Portfolios and Specifications
Table 86. Pfizer Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 87. Pfizer Main Business
Table 88. Pfizer Latest Developments
Table 89. Roche AG Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 90. Roche AG Biosimilar and Biologics Product Portfolios and Specifications
Table 91. Roche AG Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 92. Roche AG Main Business
Table 93. Roche AG Latest Developments
Table 94. AbbVie Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 95. AbbVie Biosimilar and Biologics Product Portfolios and Specifications
Table 96. AbbVie Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 97. AbbVie Main Business
Table 98. AbbVie Latest Developments
Table 99. Novartis AG Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 100. Novartis AG Biosimilar and Biologics Product Portfolios and Specifications
Table 101. Novartis AG Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 102. Novartis AG Main Business
Table 103. Novartis AG Latest Developments
Table 104. Merck Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 105. Merck Biosimilar and Biologics Product Portfolios and Specifications
Table 106. Merck Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 107. Merck Main Business
Table 108. Merck Latest Developments
Table 109. Bristol Myers Squibb Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 110. Bristol Myers Squibb Biosimilar and Biologics Product Portfolios and Specifications
Table 111. Bristol Myers Squibb Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 112. Bristol Myers Squibb Main Business
Table 113. Bristol Myers Squibb Latest Developments
Table 114. GSK Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 115. GSK Biosimilar and Biologics Product Portfolios and Specifications
Table 116. GSK Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 117. GSK Main Business
Table 118. GSK Latest Developments
Table 119. AstraZeneca Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 120. AstraZeneca Biosimilar and Biologics Product Portfolios and Specifications
Table 121. AstraZeneca Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 122. AstraZeneca Main Business
Table 123. AstraZeneca Latest Developments
Table 124. Eli Lilly Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 125. Eli Lilly Biosimilar and Biologics Product Portfolios and Specifications
Table 126. Eli Lilly Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 127. Eli Lilly Main Business
Table 128. Eli Lilly Latest Developments
Table 129. Bayer Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 130. Bayer Biosimilar and Biologics Product Portfolios and Specifications
Table 131. Bayer Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 132. Bayer Main Business
Table 133. Bayer Latest Developments
Table 134. Gilead Sciences Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 135. Gilead Sciences Biosimilar and Biologics Product Portfolios and Specifications
Table 136. Gilead Sciences Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 137. Gilead Sciences Main Business
Table 138. Gilead Sciences Latest Developments
Table 139. Amgen Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 140. Amgen Biosimilar and Biologics Product Portfolios and Specifications
Table 141. Amgen Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 142. Amgen Main Business
Table 143. Amgen Latest Developments
Table 144. Boehringer Ingelheim Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 145. Boehringer Ingelheim Biosimilar and Biologics Product Portfolios and Specifications
Table 146. Boehringer Ingelheim Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 147. Boehringer Ingelheim Main Business
Table 148. Boehringer Ingelheim Latest Developments
Table 149. Novo Nordisk Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 150. Novo Nordisk Biosimilar and Biologics Product Portfolios and Specifications
Table 151. Novo Nordisk Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 152. Novo Nordisk Main Business
Table 153. Novo Nordisk Latest Developments
Table 154. Viatris Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 155. Viatris Biosimilar and Biologics Product Portfolios and Specifications
Table 156. Viatris Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 157. Viatris Main Business
Table 158. Viatris Latest Developments
Table 159. Johnson Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 160. Johnson Biosimilar and Biologics Product Portfolios and Specifications
Table 161. Johnson Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 162. Johnson Main Business
Table 163. Johnson Latest Developments
Table 164. Sanofi Winthrop Industries Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 165. Sanofi Winthrop Industries Biosimilar and Biologics Product Portfolios and Specifications
Table 166. Sanofi Winthrop Industries Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 167. Sanofi Winthrop Industries Main Business
Table 168. Sanofi Winthrop Industries Latest Developments
Table 169. Serum Institute of India Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 170. Serum Institute of India Biosimilar and Biologics Product Portfolios and Specifications
Table 171. Serum Institute of India Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 172. Serum Institute of India Main Business
Table 173. Serum Institute of India Latest Developments
Table 174. Biocon Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 175. Biocon Biosimilar and Biologics Product Portfolios and Specifications
Table 176. Biocon Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 177. Biocon Main Business
Table 178. Biocon Latest Developments
Table 179. Intas Pharmaceuticals Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 180. Intas Pharmaceuticals Biosimilar and Biologics Product Portfolios and Specifications
Table 181. Intas Pharmaceuticals Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 182. Intas Pharmaceuticals Main Business
Table 183. Intas Pharmaceuticals Latest Developments
Table 1. Biosimilar and Biologics Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Biosimilar and Biologics Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Monoclonal Antibody
Table 4. Major Players of Vaccines
Table 5. Major Players of Recombinant Insulin
Table 6. Major Players of Growth Factors
Table 7. Major Players of Immune Modulators
Table 8. Major Players of Fusion Protein
Table 9. Major Players of Erythoprotein
Table 10. Major Players of Other
Table 11. Global Biosimilar and Biologics Sales by Type (2019-2024) & (K Units)
Table 12. Global Biosimilar and Biologics Sales Market Share by Type (2019-2024)
Table 13. Global Biosimilar and Biologics Revenue by Type (2019-2024) & ($ million)
Table 14. Global Biosimilar and Biologics Revenue Market Share by Type (2019-2024)
Table 15. Global Biosimilar and Biologics Sale Price by Type (2019-2024) & (US$/Unit)
Table 16. Global Biosimilar and Biologics Sales by Application (2019-2024) & (K Units)
Table 17. Global Biosimilar and Biologics Sales Market Share by Application (2019-2024)
Table 18. Global Biosimilar and Biologics Revenue by Application (2019-2024)
Table 19. Global Biosimilar and Biologics Revenue Market Share by Application (2019-2024)
Table 20. Global Biosimilar and Biologics Sale Price by Application (2019-2024) & (US$/Unit)
Table 21. Global Biosimilar and Biologics Sales by Company (2019-2024) & (K Units)
Table 22. Global Biosimilar and Biologics Sales Market Share by Company (2019-2024)
Table 23. Global Biosimilar and Biologics Revenue by Company (2019-2024) ($ Millions)
Table 24. Global Biosimilar and Biologics Revenue Market Share by Company (2019-2024)
Table 25. Global Biosimilar and Biologics Sale Price by Company (2019-2024) & (US$/Unit)
Table 26. Key Manufacturers Biosimilar and Biologics Producing Area Distribution and Sales Area
Table 27. Players Biosimilar and Biologics Products Offered
Table 28. Biosimilar and Biologics Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 29. New Products and Potential Entrants
Table 30. Mergers & Acquisitions, Expansion
Table 31. Global Biosimilar and Biologics Sales by Geographic Region (2019-2024) & (K Units)
Table 32. Global Biosimilar and Biologics Sales Market Share Geographic Region (2019-2024)
Table 33. Global Biosimilar and Biologics Revenue by Geographic Region (2019-2024) & ($ millions)
Table 34. Global Biosimilar and Biologics Revenue Market Share by Geographic Region (2019-2024)
Table 35. Global Biosimilar and Biologics Sales by Country/Region (2019-2024) & (K Units)
Table 36. Global Biosimilar and Biologics Sales Market Share by Country/Region (2019-2024)
Table 37. Global Biosimilar and Biologics Revenue by Country/Region (2019-2024) & ($ millions)
Table 38. Global Biosimilar and Biologics Revenue Market Share by Country/Region (2019-2024)
Table 39. Americas Biosimilar and Biologics Sales by Country (2019-2024) & (K Units)
Table 40. Americas Biosimilar and Biologics Sales Market Share by Country (2019-2024)
Table 41. Americas Biosimilar and Biologics Revenue by Country (2019-2024) & ($ Millions)
Table 42. Americas Biosimilar and Biologics Revenue Market Share by Country (2019-2024)
Table 43. Americas Biosimilar and Biologics Sales by Type (2019-2024) & (K Units)
Table 44. Americas Biosimilar and Biologics Sales by Application (2019-2024) & (K Units)
Table 45. APAC Biosimilar and Biologics Sales by Region (2019-2024) & (K Units)
Table 46. APAC Biosimilar and Biologics Sales Market Share by Region (2019-2024)
Table 47. APAC Biosimilar and Biologics Revenue by Region (2019-2024) & ($ Millions)
Table 48. APAC Biosimilar and Biologics Revenue Market Share by Region (2019-2024)
Table 49. APAC Biosimilar and Biologics Sales by Type (2019-2024) & (K Units)
Table 50. APAC Biosimilar and Biologics Sales by Application (2019-2024) & (K Units)
Table 51. Europe Biosimilar and Biologics Sales by Country (2019-2024) & (K Units)
Table 52. Europe Biosimilar and Biologics Sales Market Share by Country (2019-2024)
Table 53. Europe Biosimilar and Biologics Revenue by Country (2019-2024) & ($ Millions)
Table 54. Europe Biosimilar and Biologics Revenue Market Share by Country (2019-2024)
Table 55. Europe Biosimilar and Biologics Sales by Type (2019-2024) & (K Units)
Table 56. Europe Biosimilar and Biologics Sales by Application (2019-2024) & (K Units)
Table 57. Middle East & Africa Biosimilar and Biologics Sales by Country (2019-2024) & (K Units)
Table 58. Middle East & Africa Biosimilar and Biologics Sales Market Share by Country (2019-2024)
Table 59. Middle East & Africa Biosimilar and Biologics Revenue by Country (2019-2024) & ($ Millions)
Table 60. Middle East & Africa Biosimilar and Biologics Revenue Market Share by Country (2019-2024)
Table 61. Middle East & Africa Biosimilar and Biologics Sales by Type (2019-2024) & (K Units)
Table 62. Middle East & Africa Biosimilar and Biologics Sales by Application (2019-2024) & (K Units)
Table 63. Key Market Drivers & Growth Opportunities of Biosimilar and Biologics
Table 64. Key Market Challenges & Risks of Biosimilar and Biologics
Table 65. Key Industry Trends of Biosimilar and Biologics
Table 66. Biosimilar and Biologics Raw Material
Table 67. Key Suppliers of Raw Materials
Table 68. Biosimilar and Biologics Distributors List
Table 69. Biosimilar and Biologics Customer List
Table 70. Global Biosimilar and Biologics Sales Forecast by Region (2025-2030) & (K Units)
Table 71. Global Biosimilar and Biologics Revenue Forecast by Region (2025-2030) & ($ millions)
Table 72. Americas Biosimilar and Biologics Sales Forecast by Country (2025-2030) & (K Units)
Table 73. Americas Biosimilar and Biologics Revenue Forecast by Country (2025-2030) & ($ millions)
Table 74. APAC Biosimilar and Biologics Sales Forecast by Region (2025-2030) & (K Units)
Table 75. APAC Biosimilar and Biologics Revenue Forecast by Region (2025-2030) & ($ millions)
Table 76. Europe Biosimilar and Biologics Sales Forecast by Country (2025-2030) & (K Units)
Table 77. Europe Biosimilar and Biologics Revenue Forecast by Country (2025-2030) & ($ millions)
Table 78. Middle East & Africa Biosimilar and Biologics Sales Forecast by Country (2025-2030) & (K Units)
Table 79. Middle East & Africa Biosimilar and Biologics Revenue Forecast by Country (2025-2030) & ($ millions)
Table 80. Global Biosimilar and Biologics Sales Forecast by Type (2025-2030) & (K Units)
Table 81. Global Biosimilar and Biologics Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 82. Global Biosimilar and Biologics Sales Forecast by Application (2025-2030) & (K Units)
Table 83. Global Biosimilar and Biologics Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 84. Pfizer Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 85. Pfizer Biosimilar and Biologics Product Portfolios and Specifications
Table 86. Pfizer Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 87. Pfizer Main Business
Table 88. Pfizer Latest Developments
Table 89. Roche AG Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 90. Roche AG Biosimilar and Biologics Product Portfolios and Specifications
Table 91. Roche AG Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 92. Roche AG Main Business
Table 93. Roche AG Latest Developments
Table 94. AbbVie Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 95. AbbVie Biosimilar and Biologics Product Portfolios and Specifications
Table 96. AbbVie Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 97. AbbVie Main Business
Table 98. AbbVie Latest Developments
Table 99. Novartis AG Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 100. Novartis AG Biosimilar and Biologics Product Portfolios and Specifications
Table 101. Novartis AG Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 102. Novartis AG Main Business
Table 103. Novartis AG Latest Developments
Table 104. Merck Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 105. Merck Biosimilar and Biologics Product Portfolios and Specifications
Table 106. Merck Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 107. Merck Main Business
Table 108. Merck Latest Developments
Table 109. Bristol Myers Squibb Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 110. Bristol Myers Squibb Biosimilar and Biologics Product Portfolios and Specifications
Table 111. Bristol Myers Squibb Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 112. Bristol Myers Squibb Main Business
Table 113. Bristol Myers Squibb Latest Developments
Table 114. GSK Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 115. GSK Biosimilar and Biologics Product Portfolios and Specifications
Table 116. GSK Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 117. GSK Main Business
Table 118. GSK Latest Developments
Table 119. AstraZeneca Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 120. AstraZeneca Biosimilar and Biologics Product Portfolios and Specifications
Table 121. AstraZeneca Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 122. AstraZeneca Main Business
Table 123. AstraZeneca Latest Developments
Table 124. Eli Lilly Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 125. Eli Lilly Biosimilar and Biologics Product Portfolios and Specifications
Table 126. Eli Lilly Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 127. Eli Lilly Main Business
Table 128. Eli Lilly Latest Developments
Table 129. Bayer Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 130. Bayer Biosimilar and Biologics Product Portfolios and Specifications
Table 131. Bayer Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 132. Bayer Main Business
Table 133. Bayer Latest Developments
Table 134. Gilead Sciences Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 135. Gilead Sciences Biosimilar and Biologics Product Portfolios and Specifications
Table 136. Gilead Sciences Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 137. Gilead Sciences Main Business
Table 138. Gilead Sciences Latest Developments
Table 139. Amgen Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 140. Amgen Biosimilar and Biologics Product Portfolios and Specifications
Table 141. Amgen Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 142. Amgen Main Business
Table 143. Amgen Latest Developments
Table 144. Boehringer Ingelheim Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 145. Boehringer Ingelheim Biosimilar and Biologics Product Portfolios and Specifications
Table 146. Boehringer Ingelheim Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 147. Boehringer Ingelheim Main Business
Table 148. Boehringer Ingelheim Latest Developments
Table 149. Novo Nordisk Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 150. Novo Nordisk Biosimilar and Biologics Product Portfolios and Specifications
Table 151. Novo Nordisk Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 152. Novo Nordisk Main Business
Table 153. Novo Nordisk Latest Developments
Table 154. Viatris Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 155. Viatris Biosimilar and Biologics Product Portfolios and Specifications
Table 156. Viatris Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 157. Viatris Main Business
Table 158. Viatris Latest Developments
Table 159. Johnson Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 160. Johnson Biosimilar and Biologics Product Portfolios and Specifications
Table 161. Johnson Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 162. Johnson Main Business
Table 163. Johnson Latest Developments
Table 164. Sanofi Winthrop Industries Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 165. Sanofi Winthrop Industries Biosimilar and Biologics Product Portfolios and Specifications
Table 166. Sanofi Winthrop Industries Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 167. Sanofi Winthrop Industries Main Business
Table 168. Sanofi Winthrop Industries Latest Developments
Table 169. Serum Institute of India Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 170. Serum Institute of India Biosimilar and Biologics Product Portfolios and Specifications
Table 171. Serum Institute of India Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 172. Serum Institute of India Main Business
Table 173. Serum Institute of India Latest Developments
Table 174. Biocon Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 175. Biocon Biosimilar and Biologics Product Portfolios and Specifications
Table 176. Biocon Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 177. Biocon Main Business
Table 178. Biocon Latest Developments
Table 179. Intas Pharmaceuticals Basic Information, Biosimilar and Biologics Manufacturing Base, Sales Area and Its Competitors
Table 180. Intas Pharmaceuticals Biosimilar and Biologics Product Portfolios and Specifications
Table 181. Intas Pharmaceuticals Biosimilar and Biologics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 182. Intas Pharmaceuticals Main Business
Table 183. Intas Pharmaceuticals Latest Developments
LIST OF FIGURES
Figure 1. Picture of Biosimilar and Biologics
Figure 2. Biosimilar and Biologics Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Biosimilar and Biologics Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Biosimilar and Biologics Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Biosimilar and Biologics Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Monoclonal Antibody
Figure 10. Product Picture of Vaccines
Figure 11. Product Picture of Recombinant Insulin
Figure 12. Product Picture of Growth Factors
Figure 13. Product Picture of Immune Modulators
Figure 14. Product Picture of Fusion Protein
Figure 15. Product Picture of Erythoprotein
Figure 16. Product Picture of Other
Figure 17. Global Biosimilar and Biologics Sales Market Share by Type in 2023
Figure 18. Global Biosimilar and Biologics Revenue Market Share by Type (2019-2024)
Figure 19. Biosimilar and Biologics Consumed in Autoimmune Diseases
Figure 20. Global Biosimilar and Biologics Market: Autoimmune Diseases (2019-2024) & (K Units)
Figure 21. Biosimilar and Biologics Consumed in Infectious Diseases
Figure 22. Global Biosimilar and Biologics Market: Infectious Diseases (2019-2024) & (K Units)
Figure 23. Biosimilar and Biologics Consumed in Cardiovascular Disorders
Figure 24. Global Biosimilar and Biologics Market: Cardiovascular Disorders (2019-2024) & (K Units)
Figure 25. Biosimilar and Biologics Consumed in Other
Figure 26. Global Biosimilar and Biologics Market: Other (2019-2024) & (K Units)
Figure 27. Global Biosimilar and Biologics Sales Market Share by Application (2023)
Figure 28. Global Biosimilar and Biologics Revenue Market Share by Application in 2023
Figure 29. Biosimilar and Biologics Sales Market by Company in 2023 (K Units)
Figure 30. Global Biosimilar and Biologics Sales Market Share by Company in 2023
Figure 31. Biosimilar and Biologics Revenue Market by Company in 2023 ($ Million)
Figure 32. Global Biosimilar and Biologics Revenue Market Share by Company in 2023
Figure 33. Global Biosimilar and Biologics Sales Market Share by Geographic Region (2019-2024)
Figure 34. Global Biosimilar and Biologics Revenue Market Share by Geographic Region in 2023
Figure 35. Americas Biosimilar and Biologics Sales 2019-2024 (K Units)
Figure 36. Americas Biosimilar and Biologics Revenue 2019-2024 ($ Millions)
Figure 37. APAC Biosimilar and Biologics Sales 2019-2024 (K Units)
Figure 38. APAC Biosimilar and Biologics Revenue 2019-2024 ($ Millions)
Figure 39. Europe Biosimilar and Biologics Sales 2019-2024 (K Units)
Figure 40. Europe Biosimilar and Biologics Revenue 2019-2024 ($ Millions)
Figure 41. Middle East & Africa Biosimilar and Biologics Sales 2019-2024 (K Units)
Figure 42. Middle East & Africa Biosimilar and Biologics Revenue 2019-2024 ($ Millions)
Figure 43. Americas Biosimilar and Biologics Sales Market Share by Country in 2023
Figure 44. Americas Biosimilar and Biologics Revenue Market Share by Country in 2023
Figure 45. Americas Biosimilar and Biologics Sales Market Share by Type (2019-2024)
Figure 46. Americas Biosimilar and Biologics Sales Market Share by Application (2019-2024)
Figure 47. United States Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 48. Canada Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 49. Mexico Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 50. Brazil Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 51. APAC Biosimilar and Biologics Sales Market Share by Region in 2023
Figure 52. APAC Biosimilar and Biologics Revenue Market Share by Regions in 2023
Figure 53. APAC Biosimilar and Biologics Sales Market Share by Type (2019-2024)
Figure 54. APAC Biosimilar and Biologics Sales Market Share by Application (2019-2024)
Figure 55. China Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 56. Japan Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 57. South Korea Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 58. Southeast Asia Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 59. India Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 60. Australia Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 61. China Taiwan Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 62. Europe Biosimilar and Biologics Sales Market Share by Country in 2023
Figure 63. Europe Biosimilar and Biologics Revenue Market Share by Country in 2023
Figure 64. Europe Biosimilar and Biologics Sales Market Share by Type (2019-2024)
Figure 65. Europe Biosimilar and Biologics Sales Market Share by Application (2019-2024)
Figure 66. Germany Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 67. France Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 68. UK Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 69. Italy Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 70. Russia Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 71. Middle East & Africa Biosimilar and Biologics Sales Market Share by Country in 2023
Figure 72. Middle East & Africa Biosimilar and Biologics Revenue Market Share by Country in 2023
Figure 73. Middle East & Africa Biosimilar and Biologics Sales Market Share by Type (2019-2024)
Figure 74. Middle East & Africa Biosimilar and Biologics Sales Market Share by Application (2019-2024)
Figure 75. Egypt Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 76. South Africa Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 77. Israel Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 78. Turkey Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 79. GCC Country Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 80. Manufacturing Cost Structure Analysis of Biosimilar and Biologics in 2023
Figure 81. Manufacturing Process Analysis of Biosimilar and Biologics
Figure 82. Industry Chain Structure of Biosimilar and Biologics
Figure 83. Channels of Distribution
Figure 84. Global Biosimilar and Biologics Sales Market Forecast by Region (2025-2030)
Figure 85. Global Biosimilar and Biologics Revenue Market Share Forecast by Region (2025-2030)
Figure 86. Global Biosimilar and Biologics Sales Market Share Forecast by Type (2025-2030)
Figure 87. Global Biosimilar and Biologics Revenue Market Share Forecast by Type (2025-2030)
Figure 88. Global Biosimilar and Biologics Sales Market Share Forecast by Application (2025-2030)
Figure 89. Global Biosimilar and Biologics Revenue Market Share Forecast by Application (2025-2030)
Figure 1. Picture of Biosimilar and Biologics
Figure 2. Biosimilar and Biologics Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Biosimilar and Biologics Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Biosimilar and Biologics Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Biosimilar and Biologics Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Monoclonal Antibody
Figure 10. Product Picture of Vaccines
Figure 11. Product Picture of Recombinant Insulin
Figure 12. Product Picture of Growth Factors
Figure 13. Product Picture of Immune Modulators
Figure 14. Product Picture of Fusion Protein
Figure 15. Product Picture of Erythoprotein
Figure 16. Product Picture of Other
Figure 17. Global Biosimilar and Biologics Sales Market Share by Type in 2023
Figure 18. Global Biosimilar and Biologics Revenue Market Share by Type (2019-2024)
Figure 19. Biosimilar and Biologics Consumed in Autoimmune Diseases
Figure 20. Global Biosimilar and Biologics Market: Autoimmune Diseases (2019-2024) & (K Units)
Figure 21. Biosimilar and Biologics Consumed in Infectious Diseases
Figure 22. Global Biosimilar and Biologics Market: Infectious Diseases (2019-2024) & (K Units)
Figure 23. Biosimilar and Biologics Consumed in Cardiovascular Disorders
Figure 24. Global Biosimilar and Biologics Market: Cardiovascular Disorders (2019-2024) & (K Units)
Figure 25. Biosimilar and Biologics Consumed in Other
Figure 26. Global Biosimilar and Biologics Market: Other (2019-2024) & (K Units)
Figure 27. Global Biosimilar and Biologics Sales Market Share by Application (2023)
Figure 28. Global Biosimilar and Biologics Revenue Market Share by Application in 2023
Figure 29. Biosimilar and Biologics Sales Market by Company in 2023 (K Units)
Figure 30. Global Biosimilar and Biologics Sales Market Share by Company in 2023
Figure 31. Biosimilar and Biologics Revenue Market by Company in 2023 ($ Million)
Figure 32. Global Biosimilar and Biologics Revenue Market Share by Company in 2023
Figure 33. Global Biosimilar and Biologics Sales Market Share by Geographic Region (2019-2024)
Figure 34. Global Biosimilar and Biologics Revenue Market Share by Geographic Region in 2023
Figure 35. Americas Biosimilar and Biologics Sales 2019-2024 (K Units)
Figure 36. Americas Biosimilar and Biologics Revenue 2019-2024 ($ Millions)
Figure 37. APAC Biosimilar and Biologics Sales 2019-2024 (K Units)
Figure 38. APAC Biosimilar and Biologics Revenue 2019-2024 ($ Millions)
Figure 39. Europe Biosimilar and Biologics Sales 2019-2024 (K Units)
Figure 40. Europe Biosimilar and Biologics Revenue 2019-2024 ($ Millions)
Figure 41. Middle East & Africa Biosimilar and Biologics Sales 2019-2024 (K Units)
Figure 42. Middle East & Africa Biosimilar and Biologics Revenue 2019-2024 ($ Millions)
Figure 43. Americas Biosimilar and Biologics Sales Market Share by Country in 2023
Figure 44. Americas Biosimilar and Biologics Revenue Market Share by Country in 2023
Figure 45. Americas Biosimilar and Biologics Sales Market Share by Type (2019-2024)
Figure 46. Americas Biosimilar and Biologics Sales Market Share by Application (2019-2024)
Figure 47. United States Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 48. Canada Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 49. Mexico Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 50. Brazil Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 51. APAC Biosimilar and Biologics Sales Market Share by Region in 2023
Figure 52. APAC Biosimilar and Biologics Revenue Market Share by Regions in 2023
Figure 53. APAC Biosimilar and Biologics Sales Market Share by Type (2019-2024)
Figure 54. APAC Biosimilar and Biologics Sales Market Share by Application (2019-2024)
Figure 55. China Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 56. Japan Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 57. South Korea Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 58. Southeast Asia Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 59. India Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 60. Australia Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 61. China Taiwan Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 62. Europe Biosimilar and Biologics Sales Market Share by Country in 2023
Figure 63. Europe Biosimilar and Biologics Revenue Market Share by Country in 2023
Figure 64. Europe Biosimilar and Biologics Sales Market Share by Type (2019-2024)
Figure 65. Europe Biosimilar and Biologics Sales Market Share by Application (2019-2024)
Figure 66. Germany Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 67. France Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 68. UK Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 69. Italy Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 70. Russia Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 71. Middle East & Africa Biosimilar and Biologics Sales Market Share by Country in 2023
Figure 72. Middle East & Africa Biosimilar and Biologics Revenue Market Share by Country in 2023
Figure 73. Middle East & Africa Biosimilar and Biologics Sales Market Share by Type (2019-2024)
Figure 74. Middle East & Africa Biosimilar and Biologics Sales Market Share by Application (2019-2024)
Figure 75. Egypt Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 76. South Africa Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 77. Israel Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 78. Turkey Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 79. GCC Country Biosimilar and Biologics Revenue Growth 2019-2024 ($ Millions)
Figure 80. Manufacturing Cost Structure Analysis of Biosimilar and Biologics in 2023
Figure 81. Manufacturing Process Analysis of Biosimilar and Biologics
Figure 82. Industry Chain Structure of Biosimilar and Biologics
Figure 83. Channels of Distribution
Figure 84. Global Biosimilar and Biologics Sales Market Forecast by Region (2025-2030)
Figure 85. Global Biosimilar and Biologics Revenue Market Share Forecast by Region (2025-2030)
Figure 86. Global Biosimilar and Biologics Sales Market Share Forecast by Type (2025-2030)
Figure 87. Global Biosimilar and Biologics Revenue Market Share Forecast by Type (2025-2030)
Figure 88. Global Biosimilar and Biologics Sales Market Share Forecast by Application (2025-2030)
Figure 89. Global Biosimilar and Biologics Revenue Market Share Forecast by Application (2025-2030)
